The FDA has granted accelerated approval to Gilead’s PPAR-δ selective agonist seladelpar (Livdelzi) for primary biliary cholangitis (PBC). The approval follows a greenlight for Ipsen’s dual PPAR-α and ...
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...
Reneo Pharmaceuticals Inc.’s $93.8 million IPO last month brought renewed attention to primary mitochondrial myopathy (PMM), a genetic disorder that impairs oxidative phosphorylation, affecting mainly ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...
BOSTON -- The investigational agent seladelpar improved markers of disease activity and pruritus in patients with primary biliary cholangitis (PBC) at risk of disease progression, a phase III trial ...
Credit: Gilead. Livdelzi is supplied as a 10mg capsule. Seladelpar is a first-in-class oral, selective peroxisome proliferator-activated receptor-delta agonist. The Food and Drug Administration (FDA) ...
The FDA granted accelerated approval to seladelpar (Livdelzi) for adults with primary biliary cholangitis (PBC), a rare and chronic autoimmune disease of the bile ducts, drugmaker Gilead Sciences ...
Elafibranor, a dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, appears to be a safe and effective treatment of primary biliary cholangitis, according to a new clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results